What is B. Riley’s Forecast for OBIO Q1 Earnings?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Equities researchers at B. Riley issued their Q1 2026 earnings per share estimates for shares of Orchestra BioMed in a research report issued on Thursday, April 3rd. B. Riley analyst A. Schock forecasts that the company will post earnings of ($0.54) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. B. Riley also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.76) EPS.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). Orchestra BioMed had a negative return on equity of 107.04% and a negative net margin of 2,179.33%. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.79 million.

Several other equities analysts have also commented on the stock. Barclays started coverage on shares of Orchestra BioMed in a research report on Thursday, January 2nd. They set an “overweight” rating and a $16.00 price objective for the company. BTIG Research initiated coverage on Orchestra BioMed in a research report on Thursday, March 20th. They issued a “buy” rating and a $12.00 price target for the company. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Tuesday, April 1st. Finally, HC Wainwright lowered their price objective on Orchestra BioMed from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Orchestra BioMed has a consensus rating of “Buy” and a consensus price target of $15.00.

Orchestra BioMed Trading Down 11.3 %

NASDAQ:OBIO opened at $2.76 on Monday. The business’s 50-day moving average is $4.71 and its 200 day moving average is $5.10. Orchestra BioMed has a 12 month low of $2.65 and a 12 month high of $8.87. The company has a market capitalization of $104.92 million, a P/E ratio of -1.71 and a beta of 0.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OBIO. SG Americas Securities LLC lifted its holdings in shares of Orchestra BioMed by 26.0% in the 4th quarter. SG Americas Securities LLC now owns 12,785 shares of the company’s stock worth $51,000 after buying an additional 2,642 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Orchestra BioMed by 43.6% in the fourth quarter. Wells Fargo & Company MN now owns 13,156 shares of the company’s stock valued at $53,000 after acquiring an additional 3,992 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Orchestra BioMed in the fourth quarter valued at about $86,000. Bank of America Corp DE lifted its stake in Orchestra BioMed by 42.0% in the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after acquiring an additional 7,036 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Orchestra BioMed by 11.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company’s stock worth $148,000 after acquiring an additional 3,704 shares in the last quarter. Institutional investors own 53.55% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.